Component
Human vesicular acetylcholine transporter VAChT / SLC18A3
Human vesicular acetylcholine transporter VAChT / SLC18A3. Species, exposure and limitations are retained in each linked claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
VAChT recognizes acetylcholine and packages it into vesicles for subsequent release.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/choline-research/39806024.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78", "start_char": 0, "end_char": 1047, "text_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78"}
- experimental_model
- Human VAChT cryo-EM in apo, substrate-bound and inhibitor-bound states
- exposure
- Acetylcholine and vesamicol ligand binding
- limitations
- Packaging is distinct from synthesis and release. Structures support substrate recognition and protonation coupling, not a clinical effect of choline supplementation.
- nutrient_topic
- Choline research collection; topical membership is not evidence of a direct dietary effect. · Choline
- organism
- Human VAChT protein
- plain_language
- Making acetylcholine and loading it into a release vesicle are separate steps.
- primary_references
- [choline-p39806024] Binding mechanism and antagonism of the vesicular acetylcholine transporter VAChT. (2025). https://pubmed.ncbi.nlm.nih.gov/39806024/ DOI: 10.1038/s41594-024-01462-9
- tissue_or_cell_type
- Synaptic-vesicle transporter
Choline: metabolism, signaling and nutrient connections (2026-09-17) · lines 438–449
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human VAChT cryo-EM in apo, substrate-bound and inhibitor-bound states · source_derived_draft · unverified_draft
### choline-vacht-packaging VAChT recognizes acetylcholine and packages it into vesicles for subsequent release. Condition category: normal nutrient_topic: Choline research collection; topical membership is not evidence of a direct dietary effect. plain_language: Making acetylcholine and loading it into a release vesicle are separate steps. organism: Human VAChT protein tissue_or_cell_type: Synaptic-vesicle transporter experimental_model: Human VAChT cryo-EM in apo, substrate-bound and inhibitor-bound states limitations: Packaging is distinct from synthesis and release. Structures support substrate recognition and protonation coupling, not a clinical effect of choline supplementation. exposure: Acetylcholine and vesamicol ligand binding evidence_span: {"source_cache": "artifacts/choline-research/39806024.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78", "start_char": 0, "end_char": 1047, "text_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78"} [choline-p39806024] Binding mechanism and antagonism of the vesicular acetylcholine transporter VAChT. (2025). https://pubmed.ncbi.nlm.nih.gov/39806024/ DOI: 10.1038/s41594-024-01462-9
Complete structured claim and evidence
What acts on it
The human VAChT structure captured vesamicol in its inhibitory binding site.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/choline-research/39806024.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78", "start_char": 0, "end_char": 1047, "text_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78"}
- experimental_model
- Human VAChT cryo-EM in apo, substrate-bound and inhibitor-bound states
- exposure
- Acetylcholine and vesamicol ligand binding
- limitations
- Packaging is distinct from synthesis and release. Structures support substrate recognition and protonation coupling, not a clinical effect of choline supplementation.
- nutrient_topic
- Choline research collection; topical membership is not evidence of a direct dietary effect. · Choline
- organism
- Human VAChT protein
- plain_language
- A drug can interrupt packaging without being a choline shortage.
- primary_references
- [choline-p39806024] Binding mechanism and antagonism of the vesicular acetylcholine transporter VAChT. (2025). https://pubmed.ncbi.nlm.nih.gov/39806024/ DOI: 10.1038/s41594-024-01462-9
- tissue_or_cell_type
- Synaptic-vesicle transporter
Choline: metabolism, signaling and nutrient connections (2026-09-17) · lines 451–462
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human VAChT cryo-EM in apo, substrate-bound and inhibitor-bound states · source_derived_draft · unverified_draft
### choline-vacht-vesamicol The human VAChT structure captured vesamicol in its inhibitory binding site. Condition category: normal nutrient_topic: Choline research collection; topical membership is not evidence of a direct dietary effect. plain_language: A drug can interrupt packaging without being a choline shortage. organism: Human VAChT protein tissue_or_cell_type: Synaptic-vesicle transporter experimental_model: Human VAChT cryo-EM in apo, substrate-bound and inhibitor-bound states limitations: Packaging is distinct from synthesis and release. Structures support substrate recognition and protonation coupling, not a clinical effect of choline supplementation. exposure: Acetylcholine and vesamicol ligand binding evidence_span: {"source_cache": "artifacts/choline-research/39806024.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78", "start_char": 0, "end_char": 1047, "text_sha256": "e2c63d42f1864e1d9401293ec0c67d659eca8dbb0d571a8d1a328ec04883eb78"} [choline-p39806024] Binding mechanism and antagonism of the vesicular acetylcholine transporter VAChT. (2025). https://pubmed.ncbi.nlm.nih.gov/39806024/ DOI: 10.1038/s41594-024-01462-9
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.